Further information:InvestorsCandice KnollBlueprint Life Science Group+1 415-375-3340 Ext. firstname.lastname@example.org
DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6 th at 1:20PM ET. Dr. Heffernan will discuss Nexvet's pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company's manufacturing facility, BioNua, as well as the Company's pipeline. The presentation will be available on the investor section of Nexvet's website at http://ir.nexvet.com following the completion of the event. About Nexvet ( www.nexvet.com) Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost. Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts manufacturing in Ireland.